Dr Marie Boyd joined SIPBS from the CRUK Beatson Laboratories in July 2009 as a SULSA Reader in Translational Biology. Dr Boyd was awarded a CRUK Senior Cancer Research Fellowship in 2005 to investigate targeted radionuclide therapy for cancer. Targeted radionuclide therapy utilised radiation like a drug, that is molecules which are accrued specifically in tumours have a radioactive molecule attached, and once the radiopharmaceutical is injected into the body and it gets concentrated only in tumour cells. This results in irradiation specifically to tumour cells sparing normal tissues and thus reduction of toxic side effects.
Our research group focuses on expansion of this form of radiotherapy to more tumour types by investigation and development of novel radiopharmaceuticals and targets as well as by adopting gene therapy techniques. The group also investigate the basic biology of cellular response to radiotherapy and have a large area of research into combining radiotherapy with novel and existing drugs. The group is a multidisciplinary research group with collaborations with the signal transduction and medicinal chemistry groups within SIPBS and with other radiation biology Groups worldwide, including close links with the Mairs Group at at the CRUK Beatson Laboratories. We also have strong collaborations with industry partners in the pharmaceutical and radiochemistry sector and our strong clinical links have ensured that promising treatment schemes are readily translated into the clinic.
Dr Boyd's group is highly active in the research, industrial and clinical arena and the lab host Post docs, PhD students, research assistants and undergraduate students.
"Analysis of radiation induced biological bysander effect elicited in vitro by targeted radionuclides" Cancer Research UK
"Targeted Cancer therapy combining radionuclides gene transfer and cytotoxic drugs: from laboratory to clinic" Cancer Research UK
"Combining targeted radionuclide therapy and radiosensitisers for tumour therapy." Cancer Research UK
"Small Molecule Discovery Programme: A comprehensive multidisciplinary approach to target the inhibitory kappa B kinase pathway to discover novel therapies in prostate cancer" Cancer Research UK
"Evaluation of melanin-targeted radiotherapy in combination with cytotoxic drugs in the treatment of melanoma" CSO
"Evaluation of systemic p73 gene therapy of cancer using a novel transferrin-targeted dendrimer" Medical Research Scotland
"Assessment of [131]MIBG targeted radionuclide therapy and multi-drug treatment of neuroblastoma" Sparks
"Novel combination therapies for the treatment of medulloblastoma " Medical Research Scotland
"Exploitation of bystander effects to maximise the efficacy of n.c.a[131]MIBG used in combination with cytotoxic drugs for the treatment of neuroblastoma" Neuroblastoma Society
Publications
Joyal JL, Barrett JA, Marquis JC, Chen J, Hillier SM, Maresca KP, Boyd M, Gage K, Nimmagadda S, Kronauge JF, Friebe M, Dinkelborg L, Stubbs JB, Stabin MG, Mairs R, Pomper MG, Babich JW.
(2010) Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma.. Cancer Research70, 4045-4053
Ahmed Lawan, Sameer Al-Harthi, Laurence Cadalbert, Anthony G. McCluskey, Anne Grant, Marie Boyd, Susan Currie and Robin Plevin (2011) Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential non-redundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survival. Journal of Biological Chemistry286, 12933-12943 [DOI: 10.1074/jbc.M110.181370 ]
Mairs, R.J. & Boyd, M. (2011) Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors. Seminars in Nuclear Medicine41, 334-344
RJ Mairs and M Boyd (2009) Optimising MIBG Therapy of neuroendocrine tumours-preclinical evidence of dose maximisation and synergy. Nuclear Medicine and Biology35, S9-20
McCluskey AG,Boyd M, Pimlott SL, Babich JW, Gaze MN, Mairs RJ (2008) Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination. British Journal of Radiology81, S28-S35
Boyd M, Sorensen A, McCluskey AG, Mairs RJ (2008) Radiation quality-dependent bystander effects elicited by targeted radionuclides. Journal of Pharmacy and Pharmacology60, 951-958 [DOI: 10.1211/jpp.60.8.0002] Published (review)
Joyal JL, Barrett JA, Marquis JC, Chen J, Hillier SM, Maresca KP, Boyd M, Gage K, Nimmagadda S, Kronauge JF, Friebe M, Dinkelborg L, Stubbs JB, Stabin MG, Mairs R, Pomper MG, Babich JW.
(2010) Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma.. Cancer Research70, 4045-4053
Ahmed Lawan, Sameer Al-Harthi, Laurence Cadalbert, Anthony G. McCluskey, Anne Grant, Marie Boyd, Susan Currie and Robin Plevin (2011) Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential non-redundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survival. Journal of Biological Chemistry286, 12933-12943 [DOI: 10.1074/jbc.M110.181370 ]
Mairs, R.J. & Boyd, M. (2011) Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors. Seminars in Nuclear Medicine41, 334-344
RJ Mairs and M Boyd (2009) Optimising MIBG Therapy of neuroendocrine tumours-preclinical evidence of dose maximisation and synergy. Nuclear Medicine and Biology35, S9-20
McCluskey AG,Boyd M, Pimlott SL, Babich JW, Gaze MN, Mairs RJ (2008) Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination. British Journal of Radiology81, S28-S35
Boyd M, Sorensen A, McCluskey AG, Mairs RJ (2008) Radiation quality-dependent bystander effects elicited by targeted radionuclides. Journal of Pharmacy and Pharmacology60, 951-958 [DOI: 10.1211/jpp.60.8.0002] Published (review)
Barrett JA, Joyal JL, Hillier SM, Maresca KP, Femia FJ, Kronauge JF, Boyd M, Mairs RJ, Babich JW.
(2010) Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.. Cancer Biotherapy and Radiopharmaceuticals25, 299-308
